Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
doi: 10.3748/wjg.v28.i23.2546 Summary Keywords diabetic kidney disease, gut microbiota, short-chain fatty acids (SCFAs), probiotics, fecal microbiota transplantation (FMT) Citation Wang X, Liu X, Gong F, Jiang Y, Zhang C, Zhou W and Zhang W (2025) Targeting gut microbiota for diabetic nephropathy treatment: probiotics, dietary interventions, and fecal microbiota transplantation
2 Oral Formulation During the first quarter of 2023, Viking initiated a Phase 1 multiple ascending dose (MAD) clinical study to evaluate a novel oral formulation of VK2735
Burkhard Gke, Medical School Hamburg, Germany Updates Copyright 2019 Deacon
10.1073/pnas.75.3.1213 Proc Natl Acad Sci USA
US$ 29.42
US$ 22.49
US$ 21.36
US$ 25.85
US$ 20.69
US$ 28.79
